Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Idarubicin, cytarabine and Mylotarg with or without G-CSF priming in de novo acute myeloid leukemia
2007-006295-11Phase 2Active
- Sponsor
- Hospital de la Santa Creu i Sant Pau Research Institute
- Start
- Feb 2008
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gemtuzumab ozogamicin in acute myeloid leukemia (AML) (2 arms), sponsored by Hospital de la Santa Creu i Sant Pau Research Institute. Primary endpoint: Complete remission rate. Started Feb 2008; status: active.
02
Drugs
gemtuzumab ozogamicin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2007-006295-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006295-11.